RWS reports full-year revenues for 2021, as life sciences and linguistic validation offering outperforms on growth, and cost synergies from SDL integration top USD 21m.
Life sciences and clinical trial translation agency Conversis buys regulatory and drug safety specialist Zebra Translations, as two boutique life sciences LSPs join forces in the UK.
Paris-based IP service provider, Questel, buys New-York based patent and life sciences specialist Morningside less than four years after Co-CEOs Tom Klein and Roland Lessard took over the LSP.
Highlights from SlatorCon Remote’s Medtech Panel, featuring localization buyers from Medtronic and Varian discussing MT, regulation driving translation demand, and more.
A 44-page report on Medtech Translation and Localization, featuring industry overview, key content types and services, main buyers and suppliers, buyer insights and industry trends, and more.
UK digital healthcare provider Babylon Health localized its app to provide people in 13 more countries with access to affordable healthcare.
Drug manufacturers want EU regulators to pick one language to go on Covid-19 vaccine labels and instructions for all 27 Member States; EU consumer group says not so fast.
US Federal Circuit Court of Appeals gives no weight to certified translation of Italian patent application filed by Swiss pharmaceutical company in case versus US competitor.
The life sciences sector is one of the major buyers of translation services. Here are 12 commonly translated content types, from clinical trials to product marketing and monitoring.
TransPerfect grew revenues to USD 190m in Q1 2020, up 14% year on year. CEO warns of significant coronavirus-linked headwinds over the coming months.
With hundreds of coronavirus clinical studies underway, what role does the language industry play in facilitating the search for a vaccine? Where does linguistic validation fit in?
RWS registered its best ever revenue and profits figures in FY 2017 and declared its 14th consecutive dividend increase. Recent acquisitions in Life Sciences contribute significantly to the bottom line.
RWS reports 33.6% revenue growth and projects pre-tax profits “ahead of market expectations” for its financial year ending September 30, 2017. Market capitalization nears USD 1.3bn on the back of surge in share price.
RWS delivers yet another set of strong results as share price hovers near all-time high. Revenues are up 35% and operating profits up 28% in the first six months of the financial year. Chairman Andrew Brode says they occasionally compete with TransPerfect but would never consider buying them.
As global corporations optimize procurement across their global operations, they look to consolidate translation spend in a single framework. At SlatorCon London, Steve Kirk, Chief Procurement Officer at QuintilesIMS, discussed how the world’s largest clinical research organization manages language services.
Join over 15,500 subscribers and get the latest language industry intelligence every Friday
Your information will not be shared with third parties. No Spam.
This will close in 0 seconds